{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:42:55Z","timestamp":1792698175858,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019481","name":"Southwestern Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jacl.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T05:25:47Z","timestamp":1729142747000},"page":"178-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Complex dyslipidemia induced by lorlatinib therapy: A case study"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5839-1943","authenticated-orcid":false,"given":"Julianna","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhimanyu","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2024.10.003_bib0001","series-title":"NDA\/BLA Multi-Disciplinary Review and Evaluation of 210868 - Lorlatinib","year":"2016"},{"key":"10.1016\/j.jacl.2024.10.003_bib0002","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2020.07.022","article-title":"GLASS: global lorlatinib for ALK(+) and ROS1(+) retrospective study: real world data of 123 NSCLC patients","volume":"148","author":"Peled","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jacl.2024.10.003_bib0003","unstructured":"Prescribing Information-Lorbrena. U.S. Food & Drug Administration. 2018. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed October 3, 2023."},{"issue":"21","key":"10.1016\/j.jacl.2024.10.003_bib0004","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2024.10.003_bib0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10157-020-01957-x","article-title":"The risk of nephrotic syndrome with non-VEGF inhibitory antineoplastic drugs: from viewpoint of the adverse event reports in Japan","volume":"25","author":"Okada","year":"2021","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"10.1016\/j.jacl.2024.10.003_bib0006","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1078155220961549","article-title":"Lorlatinib induced proteinuria: a case report","volume":"27","author":"Lee","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"8","key":"10.1016\/j.jacl.2024.10.003_bib0007","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1177\/10781552211004698","article-title":"A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy","volume":"27","author":"McGee","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"8","key":"10.1016\/j.jacl.2024.10.003_bib0008","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.jtho.2018.03.033","article-title":"Minimal change disease induced by lorlatinib","volume":"13","author":"Betton","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.jacl.2024.10.003_bib0009","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/JTO.0b013e3182a02546","article-title":"Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA\/B non-small-cell lung cancer","volume":"8","author":"Choy","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.jacl.2024.10.003_bib0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/hrt.2008.149088","article-title":"Radiation induced heart disease: systemic disorders in heart disease","volume":"95","author":"Heidenreich","year":"2009","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.jacl.2024.10.003_bib0011","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.jacl.2024.10.003_bib0013","doi-asserted-by":"crossref","first-page":"9986","DOI":"10.3390\/ijms23179986","article-title":"Silibinin suppresses the hyperlipidemic effects of the ALK-tyrosine kinase inhibitor lorlatinib in hepatic cells","volume":"23","author":"Verdura","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jacl.2024.10.003_bib0014","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.3390\/nu7064995","article-title":"Hepatic steatosis as a marker of metabolic dysfunction","volume":"7","author":"Fabbrini","year":"2015","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.jacl.2024.10.003_bib0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/curroncol28010029","article-title":"Evaluation and management of dyslipidemia in patients treated with lorlatinib","volume":"28","author":"Blais","year":"2021","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.jacl.2024.10.003_bib0016","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1007\/s12325-020-01365-3","article-title":"Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners","volume":"37","author":"Reed","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2024.10.003_bib0017","doi-asserted-by":"crossref","first-page":"107535","DOI":"10.1016\/j.lungcan.2024.107535","article-title":"A pragmatic guide for management of adverse events associated with lorlatinib","volume":"191","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.jacl.2024.10.003_bib0018","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical management of adverse events associated with lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287424002617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287424002617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T04:13:08Z","timestamp":1742011988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287424002617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1933287424002617"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2024.10.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complex dyslipidemia induced by lorlatinib therapy: A case study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}